Replies to post #137093 on Biotech Values

[biomaven0]

>first SNTA ALK+ HSP90 inhibitor trial is in crizotinib-naive patients rather than failures

But there they are adding-on to standard-of-care (crizotinib) rather than replacing it.

Peter